Application for quotation of +securities
Announcement Summary
For personal use only
Entity name
AVECHO BIOTECHNOLOGY LIMITED
Announcement Type
New announcement
Date of this announcement
Monday January 10, 2022
The +securities to be quoted are:
+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer
Total number of +securities to be quoted
ASX +security | Number of +securities to | ||
code | Security description | be quoted | Issue date |
AVE | ORDINARY FULLY PAID | 1,696,000 | 10/01/2022 |
Refer to next page for full details of the announcement
Application for quotation of +securities | 1 / 7 |
Application for quotation of +securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
AVECHO BIOTECHNOLOGY LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 | Registered number type | Registration number |
ACN | 056482403 | |
1.3 | ASX issuer code | |
AVE |
- The announcement is New announcement
- Date of this announcement
10/1/2022
Application for quotation of +securities | 2 / 7 |
Application for quotation of +securities
Part 2 - Type of Issue
For personal use only
2.1 The +securities to be quoted are:
+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer
2.2 The +securities to be quoted are:
Additional +securities in a class that is already quoted on ASX ("existing class")
Application for quotation of +securities | 3 / 7 |
Application for quotation of +securities
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
For personal use only
Additional +securities to be quoted in an existing class issued under an +employee incentive scheme
FROM (Existing Class)
ASX +security code and description
No security currently exists
FROM (Existing Class) +Security description
N/A
TO (Existing Class)
ASX +security code and description
AVE : ORDINARY FULLY PAID
Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer
1,696,000
Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02243491-3A542742?access_token=83 ff96335c2d45a094df02a206a39ff4
Are any of these +securities being issued to +key management personnel (KMP) or an +associate Yes
Provide details of the KMP or +associates being issued +securities
Name of KMP | Name of registered holder | Number of +securities | |
908,000 | |||
Dr Paul Gavin | Mr Paul David Gavin | ||
788,000 | |||
Dr Roksan Libinakis | Ms Roksani Libinakis | ||
Issue date 10/1/2022
Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued
Application for quotation of +securities | 4 / 7 |
Application for quotation of +securities
+securities in that class? Yes
only | |||
Issue details | |||
Number of +securities to be quoted | |||
1,696,000 | |||
Are the +securities being issued for a cash consideration? | |||
use | No | ||
Please describe the consideration being provided for the +securities | |||
Nil | |||
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the | |||
+securities to be quoted | |||
0.015000 | |||
personalFor | Any other information the entity wishes to provide about the +securities to be quoted | ||
The securities are being issued in respect of Short Term Incentives issued under the Company's Equity Incentive Plan | |||
Rules. | |||
Application for quotation of +securities | 5 / 7 |
This is an excerpt of the original content. To continue reading it, access the original document here.